Kratom occupies an unusual regulatory gray zone — marketed as a botanical supplement, used for pain relief and opioid withdrawal, yet carrying pharmacological properties that overlap meaningfully with opioid receptor agonism. A comprehensive surveillance dataset now offers the clearest longitudinal picture yet of what happens when kratom exposures go wrong at scale, and the numbers warrant closer attention from clinicians and consumers alike.
Analysis of 13,194 kratom-related calls to U.S. Poison Centers spanning January 2016 through July 2025 reveals a pattern of steady growth that sharply accelerated in 2025. The affected population skewed male (68%) with a mean age of 32, consistent with prior demographic snapshots. Critically, 85% of cases required either a healthcare facility visit or referral. Among those, 16.5% were admitted to the ICU — a striking proportion for a substance widely perceived as benign — while 15.1% went to non-ICU wards and 6.2% were directed to psychiatric facilities. A total of 219 deaths were recorded over the period, with the majority (176) involving polysubstance exposure. Roughly 10% of all cases involved major effects defined as potentially life-threatening signs or symptoms. Single-substance exposures in 2025 showed a statistically distinct outcome distribution compared to prior years, though polysubstance cases did not differ significantly.
This dataset carries important interpretive caveats: poison center data reflects only exposures severe enough to prompt a call, almost certainly undercounting total kratom-related harms. The surge in 2025 cases may partly reflect heightened public and media attention to kratom rather than a true spike in toxicity, though the new concentrated extracts entering the market make a genuine dose-escalation explanation plausible. The 1.6% death rate, while seemingly low in absolute terms, is non-trivial for a substance with no formal clinical indication in the United States. For practitioners, this study reinforces the importance of asking about kratom use in patients presenting with unexplained opioid-like toxidromes or cardiovascular instability. The finding is confirmatory and epidemiologically valuable rather than paradigm-shifting, but its scale and duration make it among the most rigorous adverse-event characterizations of kratom to date.